Press "Enter" to skip to content

Rafael Pharmaceuticals, Ono Pharmaceutical to accelerate clinical development of cancer drug candidate CPI-613 – Pharmaceutical Business Review

admin 0

Rafael Pharmaceuticals, Ono Pharmaceutical to accelerate clinical development of cancer drug candidate CPI-613  Pharmaceutical Business Review

Rafael Pharmaceuticals, a leader in the growing field of cancer metabolism-based therapeutics, has entered into an out-licensing agreement with Ono …

“lymphoma cancer” – Google News

(Visited 1 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *